February 4, 2008 - Tryton Medical Inc. said it has received CE Mark approval for its Side-Branch Stent, a cobalt chromium balloon-expandable coronary stent specifically developed for the complete treatment of the entire spectrum of coronary artery bifurcation disease.
Approximately 540,000 annual procedures are performed to address bifurcation lesions, accounting for 20% of all coronary lesions treated. With the exception of Tryton's stent, no dedicated solution exists today that fully addresses these lesions, according to the company.